0001237899-20-000039.txt : 20200831 0001237899-20-000039.hdr.sgml : 20200831 20200831163749 ACCESSION NUMBER: 0001237899-20-000039 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200827 FILED AS OF DATE: 20200831 DATE AS OF CHANGE: 20200831 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LAROSA JOSEPH J CENTRAL INDEX KEY: 0001238303 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 201151951 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2020-08-27 0 0000872589 REGENERON PHARMACEUTICALS, INC. REGN 0001238303 LAROSA JOSEPH J 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 0 1 0 0 EVP General Counsel and Secret Common Stock 2020-08-27 4 M 0 6000 52.03 A 20438 D Common Stock 2020-08-27 4 F 0 3197 614.87 D 17241 D Common Stock 2020-08-27 4 M 0 4000 52.03 A 21241 D Common Stock 2020-08-27 4 F 0 2131 614.87 D 19110 D Common Stock 2020-08-31 4 S 0 4672 615.04 D 14438 D Common Stock 287 I By 401(k) Plan Non-Qualified Stock Option (right to buy) 52.03 2020-08-27 4 M 0 6000 0.0 D 2021-12-16 Common Stock 6000 4000 D Non-Qualified Stock Option (right to buy) 52.03 2020-08-27 4 M 0 4000 0.0 D 2021-12-16 Common Stock 4000 0 D Represents volume-weighted average price of sales of 4,672 shares of Company stock on August 31, 2020 at prices ranging from $615.00 to $615.40. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 31, 2020 at each separate price. With respect to 6,000 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 4,000 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant. /s/**Joseph J. LaRosa 2020-08-31